Additionally, the combination of CDK4/6i and anti-HER2 targeting has been found to overcome anti-HER2 resistance, synergistically inhibiting cell proliferation, controlling tumor growth in vivo, and delaying tumor recurrence. This evidence concerns the gene ERBB2 and neoplasm.